Subjects will receive and intravenous infusion of 500 mls of Convalescent COVID 19 Plasma.

COVID 19

Subjects will be transfused intravenously with 500 mls of convalescent COVID 19 plasma

Convalescent COVID 19 Plasma

The Christ Hospital

University Hospitals Cleveland Medical Center

CoVID-19 Plasma in Treatment of COVID-19 Patients

Convalescent CoVID-19 Plasma in the Treatment of High Risk CoVID-19 Disease

Reduce mortality of high risk COVID 19 disease compared with historic precedent cohorts (35-50%)

Reduce the duration of mechanical ventilation in high risk COVID 19 disease compared with historic precedent cohorts (30-60%)

Reduce the time a participant will remain on the ventilator.

Data on the number of participants with treatment related adverse events will be assessed to determine the safety and tolerability of convalescent plasma.

Dean Kereiakes

Prinicipal Investigator

Heart Failure

Acute Myocardial Infarction

Hypertension

Gennimatas General State Hospital

2nd Cardiology Department,

Cardiology University Clinic

Eplerenone in Heart Failure Treatment

A Non-interventional, Multicenter, Observational Clinical Trial to Assess Eplerenone Treatment in Patients With Heart Failure.

Elpen Pharmaceutical Co. Inc.

placebo of oseltamivir phosphate and placebo of Banlangen(Radix Isatidis) granules.

Banlangen(Radix Isatidis) granules and placebo of oseltamivir phosphate

oseltamivir phosphate and placebo of Banlangen(Radix Isatidis) granules

Influenza

placebo of oseltamivir phosphate

oseltamivir phosphate

Banlangen (Radix Isatidis) granules

placebo of Banlangen(Radix Isatidis) granules

Guangzhou Institute of Respiratory Disease

Banlangen Granules Anti-seasonal Influenza Study

Banlangen Granules Anti-seasonal Influenza Study: a Randomized, Double Blind, Positive and Placebo Controlled，Clinical Study.

The primary end point was the duration of illness which was defined as the time from onset of symptoms to the alleviation of the ten influenza-like symptoms including , nasal obstruction, running nose, cough, sore throat, headache, fatigue, myalgia, chills and sweating.

The time to defervescence, defined as the time from the first dose of study medication to the time when the body temperature declined to lower than 37.4ºC and was sustained for at least 24 hours.

viral shedding duration, defined as the time from the illness onset to the first time the viral nucleic acid test was negative

the severity of the disease,assessed by an area under the curve (AUC) analysis of a total of nine influenza-like symptom scores, the AUC was calculated as the product of the daily symptom scores times the duration of illness

incidence of secondary complications of influenza

Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited

Advanced Cancer

the role of physical activity as a Quality of Life intervention

Home-based physical activity program

Cross Cancer Institute

The Feasibility of Physical Activity in Advanced Cancer Patients

A Pilot Study to Explore the Role of Physical Activity as a Quality of Life Intervention in Advanced Cancer Patients

AHS Cancer Control Alberta

Hypercholesterolemia

3,5-Diiodothyropropionic acid (DITPA) therapy

Johns Hopkins Bayview Medical Center

Study of 3,5-Diiodothyropropionic Acid (DITPA) in Hypercholesterolemic Patients

A Randomized, Double-Blind Placebo-Controlled Study of 3,5-diiodothyropropionic Acid (DITPA) in Combination With Standard Therapy to Attain NCEP ATP III Goal for LDL Cholesterol in Hypercholesterolemic Patients

myocarditis/fatigue

CoVID-19 Plasma in Treatment of COVID-19 Patients

Eplerenone in Heart Failure Treatment

Banlangen Granules Anti-seasonal Influenza Study

The Feasibility of Physical Activity in Advanced Cancer Patients

Study of 3,5-Diiodothyropropionic Acid (DITPA) in Hypercholesterolemic Patients

Database tanaman obat terlengkap yang didukung oleh sains